A Study Explore JS001+JS002 in Patients With Advanced Cancer
Status:
Not yet recruiting
Trial end date:
2024-04-27
Target enrollment:
Participant gender:
Summary
This open-label phase I clinical study with clinical development phase will evaluate the
safety, tolerability, pharmacokinetics and preliminary efficacy of JS002 combined with
Toripalimab in advanced cancer patients, who has failed standard therapy OR could not
tolerate standard therapy OR refused/had no standard therapy.
This study is divided into two parts:
Part A. JS002 combined with Toripalimab dose escalation and dose expansion phase; Part
B.JS002 combined with Toripalimab clinical expansion phase.